This might be old news by now but have anyone seen this

New Post Public Reply Private Reply Replies (2) Message Board
BIELsince2009
650
This might be old news by now but have anyone seen this yet?

BIEL will heal! Heal with BIEL!!

Reference: http://www.voxy.co.nz/health/5/334200

Expert presents evidence for innovative drug-free pain management device
Thursday, 14 March, 2019 - 12:33
Mundipharma was pleased to welcome Biomedical Engineer Dr Sree Koneru to Australia to give a presentation on the innovative pain management device, ActiPatch, which he helped develop.

ActiPatch uses electromagnetic pulse therapy to provide long-lasting pain relief.

Dr Koneru is the Vice President of Product Development for Bioelectronics and visited Australia to present the clinical evidence behind ActiPatch at the Australian Pharmacy Conference on the Gold Coast.

You can watch Dr Koneru discussing ActiPatch on Chanel Seven’s Weekend Sunrise here.

"The new understanding of chronic pain is that nerves ‘memorise’ the initial pain from injury and over time, become hyperreactive," Dr Koneru said. "When used over a painful area, ActiPatch’s pulsed signal is absorbed by tissue and disrupts hyperactivity of the nerves, resulting in lasting relief."

Electromagnetic pulse therapy helps to relieve pain from mild osteoarthritis and general musculoskeletal pain in the back, knee, heel and other muscle joints. It is also ideal for strains, sprains and other painful conditions. The therapy is completely sensation free, with no heat, tingling sensations or vibration. ActiPatch is drug-free and can be safely used with any other medications.

A registry studyi of more than 5,000 chronic pain sufferers using ActiPatch indicated that:

- More than 65% per cent reported a clinically meaningful reduction in pain from a wide variety of causes and locations of pain

- The average pain reduction reported in these individuals was 57%

- The 3-month follow-up showed sustained pain relief, decreased oral analgesic

medication use and quality of life improvement.

"ActiPatch uses low-level therapy to allow 24/7 use and, as it doesn’t require skin contact, can be used over bandages and clothing," said Dr Koneru. "Can also be used by people with metallic implants and when not placed directly over them, electronic devices such as pacemakers/defibrillators."

Mundipharma recently acquired the exclusive Australian and New Zealand distribution rights for ActiPatch, reinforcing its commitment to the multimodal approach to pain management. This multimodal approach includes cognitive behavioural therapies, physical therapies and pharmacological therapies.

"Mundipharma has worked collaboratively with healthcare professionals to provide appropriate access to pain relief over the past 20 years," said Jane Orr, Managing Director of Mundipharma Australia and New Zealand. "Our work with leading clinicians and reputation as a trusted medical advisor will enable us to help more patients benefit from this therapy."

BioElectronics Corporation (BIEL) Stock Research Links

BIEL Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 307

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 211

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 246

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
EZaccessMD Data Breach: Class Action Lawsuit Looms

Updated Category News Views 694

Data breaches are the bogeyman no one wants lurking in the shadows, and when it’s your personal info at stake, folks rightfully squirm. This recent fiasco at EZaccessMD is one of those unsettling incidents. The word on the street isn't pretty: sensitive medical data has slipped through the cracks, leaving Edelson Lechtzin LLP, a heavyweight in class action maneuvers, to...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 63

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 351

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 239

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 105

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 27

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 180

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading

Top 5 Most Recently Viewed Articles

HD Hyundai Sparks Fusion Hopes with ITER Milestone

Updated Category News Views 9

Hold on to Your Hard Hats, Fusion Milestone Achieved Look who's making waves in the world of nuclear fusion. HD Hyundai Heavy Industries has hit a crucial benchmark in the ITER nuclear fusion project. This ain't your run-of-the-mill accomplishment, folks. We're talking about completing the assembly of some of the most complex and intricately designed machinery known to...

Continue Reading
ChemoMetec Boosts Financial Outlook with Anticipated Growth

Updated Category News Views 353

ChemoMetec Boosts Financial Outlook Amid Growing Interest ChemoMetec is excited to announce an upgrade in its financial guidance as the company sees a growing demand for its pioneering technologies, particularly the highly regarded XcytoMatic platform. This surge in interest bodes well for the company's revenue and profit, reflecting a positive trajectory as it approaches...

Continue Reading
GDS Holdings Completes Successful C-REIT IPO on Shanghai Exchange

Updated Category News Views 200

GDS Holdings Limited Celebrates C-REIT IPO Success GDS Holdings Limited, known as GDS, is thrilled to announce that it has successfully completed its initial public offering of its China REIT, or C-REIT, on the Shanghai Stock Exchange. This milestone marks an exciting moment for the company and its stakeholders as market interest surpassed expectations. Highlighting the...

Continue Reading
Innovative E-Waste Solutions from Techbros Redefine Recycling

Updated Category News Views 273

AI-Driven E-Waste Innovation from Techbros In a remarkable leap towards sustainability and innovative technology, Techbros Electronic Recycling proudly announces the launch of the Southwest's first fully integrated AI-driven IT asset disposition (ITAD) and e-waste processing facility. This state-of-the-art facility exemplifies the future of electronics recycling by...

Continue Reading
SageSure Welcomes Insurance Veteran Peter Hearn to Board

Updated Category News Views 268

SageSure Welcomes New Board Member SageSure, one of the largest managing general underwriters that focus on markets exposed to catastrophe risks, has taken a significant step by appointing Peter Hearn to its Board of Managers. This strategic move is anticipated to bolster the company’s leadership and industry insights. Peter Hearn's Impressive Background Peter Hearn...

Continue Reading